Home » Stocks » CHRS

Coherus BioSciences, Inc. (CHRS)

Stock Price: $14.50 USD 0.48 (3.42%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $14.30 -0.20 (-1.38%) Jun 11, 6:31 PM
Market Cap 1.10B
Revenue (ttm) 442.68M
Net Income (ttm) -76.28M
Shares Out 72.83M
EPS (ttm) -1.06
PE Ratio n/a
Forward PE 32.89
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $14.50
Previous Close $14.02
Change ($) 0.48
Change (%) 3.42%
Day's Open 14.26
Day's Range 14.10 - 14.50
Day's Volume 741,971
52-Week Range 12.90 - 22.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab plus chemotherapy for the f...

1 week ago - Benzinga

REDWOOD CITY, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Car...

1 month ago - GlobeNewsWire

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -2733.33% and -15.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Coherus BioSciences (NASDAQ:CHRS) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 97.92% year over year to $0.01, which ...

1 month ago - Benzinga

REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 28, 2021, the compensation committee o...

1 month ago - GlobeNewsWire

REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be relea...

1 month ago - GlobeNewsWire

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Blade--Blade Therapeutics announces the appointment of Jean-Frédéric Viret, Ph.D., as Chief Financial Officer (CFO) effective immediately.

2 months ago - Business Wire

Their recent struggles may soon give way to rising market interest and more lucrative returns.

Other stocks mentioned: IRWD, SUPN
3 months ago - The Motley Fool

REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in ...

3 months ago - GlobeNewsWire

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 -  - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with firs...

3 months ago - GlobeNewsWire

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: ILMN
3 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has acc...

3 months ago - GlobeNewsWire

Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosciences Co....

Other stocks mentioned: ABBV, AMGN, BMY, MRK, RHHBY
4 months ago - GuruFocus

REDWOOD CITY, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021, the compensation committee ...

4 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Dir...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Morgan He...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation committee...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation committee...

6 months ago - GlobeNewsWire

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

7 months ago - Zacks Investment Research

Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

7 months ago - Zacks Investment Research

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: ILMN
7 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market c...

7 months ago - GlobeNewsWire

Coherus develops and markets biosimilar versions of blockbuster biologic products.

8 months ago - Seeking Alpha

The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?

10 months ago - The Motley Fool

Coherus BioSciences' (CHRS) CEO Denny Lanfear on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

– Second Quarter UDENYCA® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million –

10 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effec...

10 months ago - GlobeNewsWire

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects.

Other stocks mentioned: BIIB, GEN, LXRX, SLRX
10 months ago - Benzinga

REDWOOD CITY, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after marke...

10 months ago - GlobeNewsWire

The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.

1 year ago - The Motley Fool

One way to increase the chances of finding high-quality investments is to look for fairly priced stocks of companies that have good financial conditions and are expected to improve their net earnings pe...

Other stocks mentioned: DECK, OMAB
1 year ago - GuruFocus

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Coherus: Branded Biosimilar Strategy, Cash Reserve, Revenue Stream

1 year ago - Seeking Alpha

Coherus Biosciences: Worth The Risks

1 year ago - Seeking Alpha

These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.

Other stocks mentioned: DTIL
1 year ago - The Motley Fool

Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.

Other stocks mentioned: BSTC, CBZ, DHT, EURN, ITGR, ROCK
1 year ago - Zacks Investment Research

REDWOOD CITY, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate pri...

1 year ago - GlobeNewsWire

REDWOOD CITY, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and other condi...

1 year ago - GlobeNewsWire

COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020 COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020

1 year ago - GlobeNewsWire

Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.

Other stocks mentioned: ABBV, BRG, HII, IBP
1 year ago - Zacks Investment Research

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimuma... [Read more...]

Industry
Biotechnology
IPO Date
Nov 6, 2014
CEO
Dennis Lanfear
Employees
310
Stock Exchange
NASDAQ
Ticker Symbol
CHRS
Full Company Profile

Financial Performance

In 2020, CHRS's revenue was $475.82 million, an increase of 33.63% compared to the previous year's $356.07 million. Earnings were $132.24 million, an increase of 47.21%.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is 25.25, which is an increase of 74.14% from the latest price.

Price Target
$25.25
(74.14% upside)
Analyst Consensus: Buy